December 21, 2017 / 10:52 PM / 6 months ago

BRIEF-Xbrane says expect to enter into agreement for out-licensing of Spherotide to China in Q1 2018​

* REG-XBRANE BIOPHARMA INFORMS ABOUT ONGOING NEGOTIATIONS CONCERNING OUT-LICENSING OF SPHEROTIDE TO CHINA

* XBRANE IS IN DISCUSSIONS AND NEGOTIATIONS WITH POTENTIAL PARTNERS REGARDING OUT-LICENSING OF SPHEROTIDE AND XLUCANE​

* ‍FINAL NEGOTIATION FOR AGREEMENT TOOK PLACE DURING CHINESE PARTNER'S VISIT IN SWEDEN AND IN ITALY IN DECEMBER​

* ‍ENTERING OF AGREEMENT IS EXPECTED TO TAKE PLACE DURING Q1 OF 2018​

* ONE OF THESE NEGOTIATIONS CONCERNS OUT-LICENSING OF RIGHTS TO SELL, MARKET SPHEROTIDE IN CHINA TO A LARGE CHINESE COMPANY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below